Akero Therapeutics Inc
AKRO54.140USD
+0.100+0.19%
收盤 11/10, 16:00（美東）報價延遲15分鐘
4.34B總市值
虧損本益比TTM
關於 Akero Therapeutics Inc 公司
Akero Therapeutics, Inc. 是一家臨牀階段公司。該公司正在爲患有嚴重代謝疾病且醫療需求尚未得到滿足的患者開發轉化療法，包括代謝功能障礙相關脂肪性肝炎 (MASH)，這是一種尚無任何獲批療法的疾病。Efruxifermin (EFX) 是其用於治療 MASH 的主要候選產品，目前正在進行 IIb 期 SYMMETRY、III 期 SYNCHRONY 組織學和 III 期 SYNCHRONY 真實世界研究中進行評估。III 期 SYNCHRONY 計劃以兩項 IIb 期臨牀試驗的結果爲基礎，即針對肝硬化前期 MASH 患者的 HARMONY 研究和針對 MASH 導致的肝硬化患者的 SYMMETRY 研究。EFX 是成纖維細胞生長因子 21 (FGF21) 的類似物，FGF21 是一種內源性表達的激素，可防止細胞應激並調節全身脂質、碳水化合物和蛋白質的代謝。 EFX 旨在提供方便的每週一次劑量。
Akero Therapeutics Inc簡介
公司代碼AKRO
公司名稱Akero Therapeutics Inc
上市日期Jun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
員工數量63
證券類型Ordinary Share
年結日Jun 20
公司地址601 Gateway Boulevard, Suite 350
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94080
電話16504876488
網址https://akerotx.com/
公司代碼AKRO
上市日期Jun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
Akero Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
393.38K
+51.69%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
217.63K
+13.41%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+30.32%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott A. Gangloff
Mr. Scott A. Gangloff
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Judy Chou, Ph.D.
Dr. Judy Chou, Ph.D.
Independent Director
Independent Director
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
393.38K
+51.69%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
217.63K
+13.41%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+30.32%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
--
-100.00%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 9月3日 週三
更新時間: 9月3日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Janus Henderson Investors
8.19%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.15%
The Vanguard Group, Inc.
5.48%
其他
66.56%
持股股東
持股股東
佔比
Janus Henderson Investors
8.19%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.15%
The Vanguard Group, Inc.
5.48%
其他
66.56%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
47.16%
Investment Advisor
33.05%
Hedge Fund
22.49%
Private Equity
9.32%
Research Firm
3.22%
Venture Capital
3.01%
Individual Investor
1.29%
Foundation
0.41%
Pension Fund
0.32%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
509
95.38M
115.92%
-917.24K
2025Q2
491
87.62M
109.91%
-627.50K
2025Q1
495
89.01M
111.79%
+1.41M
2024Q4
453
76.50M
96.29%
-13.73M
2024Q3
445
77.37M
111.97%
-14.20M
2024Q2
428
76.12M
110.88%
-16.59M
2024Q1
421
77.80M
117.45%
+1.74M
2023Q4
401
63.49M
113.86%
-5.60M
2023Q3
387
61.40M
112.62%
-2.96M
2023Q2
363
60.44M
111.44%
+4.13M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Janus Henderson Investors
6.74M
8.42%
-330.09K
-4.67%
Jun 30, 2025
General Atlantic LLC
5.73M
7.17%
+500.00K
+9.55%
Jun 30, 2025
RTW Investments L.P.
5.48M
6.85%
-1.94M
-26.17%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.06M
6.33%
-421.07K
-7.68%
Jun 30, 2025
The Vanguard Group, Inc.
4.52M
5.65%
+297.51K
+7.05%
Jun 30, 2025
T. Rowe Price Associates, Inc.
4.42M
5.53%
-310.43K
-6.56%
Jun 30, 2025
Deep Track Capital LP
3.04M
3.8%
-167.67K
-5.22%
Jun 30, 2025
Avoro Capital Advisors LLC
3.50M
4.38%
+3.50M
--
Jun 30, 2025
Wellington Management Company, LLP
3.41M
4.26%
-2.53M
-42.56%
Jun 30, 2025
State Street Investment Management (US)
2.75M
3.43%
+250.82K
+10.05%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Simplify Propel Opportunities ETF
10.44%
ALPS Medical Breakthroughs ETF
2.19%
SPDR S&P Biotech ETF
1.64%
AltShares Merger Arbitrage ETF
1.63%
Direxion Daily S&P Biotech Bull 3X Shares
0.86%
Virtus LifeSci Biotech Clinical Trials ETF
0.64%
Tema Heart & Health ETF
0.63%
ProShares Ultra Nasdaq Biotechnology
0.39%
Invesco Nasdaq Biotechnology ETF
0.38%
iShares Biotechnology ETF
0.32%
查看更多
Simplify Propel Opportunities ETF
佔比10.44%
ALPS Medical Breakthroughs ETF
佔比2.19%
SPDR S&P Biotech ETF
佔比1.64%
AltShares Merger Arbitrage ETF
佔比1.63%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.86%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.64%
Tema Heart & Health ETF
佔比0.63%
ProShares Ultra Nasdaq Biotechnology
佔比0.39%
Invesco Nasdaq Biotechnology ETF
佔比0.38%
iShares Biotechnology ETF
佔比0.32%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
